Virscio Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Employee Data

  • Virscio has 58 Employees.(i)
  • Virscio grew their employee count by 45% last year.

Virscio's People

NameTitleEmail/Phone
1
CEO & CSOReveal Email/Phone
2
Chief Business Officer, Co-founderReveal Email/Phone
3
Chief VeterinarianReveal Email/Phone
4
Chief Technology OfficerReveal Email/Phone
5
VP PeopleReveal Email/Phone
6
Histology DirectorReveal Email/Phone
7
Associate Director Ophthalmic ResearchReveal Email/Phone
8
Senior Director Research and Safety AssessmentReveal Email/Phone
9
Director Research OperationsReveal Email/Phone
10
Director TranslationReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-80%N/AN/A
#2
$4.3M288%N/AN/A
#3
$9.8M66-11%N/AN/A
#4
$1.4M9350%N/AN/A
#5
$16.6M107-23%N/AN/A
#6
$4.5M29-22%N/AN/A
#7
$1.7M1157%N/AN/A
#8
$2.3M15-6%N/AN/A
#9
$0.3M4-43%N/AN/A
#10
$4M260%N/AN/A
Add Company

What Is Virscio?

Virscio is a specialty translational research organization developing and providing innovative in vivo disease modeling and related preclinical research and development services to meet the preclinical, translational, and regulatory research needs of the pharmaceutical and life sciences industry. We specialize in the fields of ophthalmology, central nervous system, cardiovascular and metabolic related disease and disorders, and have advanced discovery and development programs for a wide range of sponsors, collaborators, and partners around the world, ranging from large pharmaceutical companies and venture-backed biotechnology companies to academic teams seeking to apply the most cutting edge research and development strategies in the most efficient and robust manner.

keywords:N/A

N/A

Total Funding

58

Number of Employees

N/A

Revenue (est)

45%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.9M5816%N/A
#2
$9.4M589%N/A
#3
$9.4M58-6%N/A
#4
$14.1M5849%N/A
#5
$21.2M597%N/A